Blog
Medtech news, market engineering best practices, and updates.
Find our playbooks, ai models, articles about the medtech, and guest blogs here, updated weekly.
Find our playbooks, ai models, articles about the medtech, and guest blogs here, updated weekly.
The 3 questions pre-traction medtech founders should ask any medical device marketing agency before signing, and why most agencies fail the market engineering test.
How pre-traction medtech founders should evaluate healthcare marketing agencies versus medtech specialists, and the 4 questions that reveal which one actually knows the buyer.
Should a pre-traction medtech founder hire a life sciences marketing agency? Why market engineering practice builds markets while agencies run campaigns.
What Axonics Knew About Medical Device Sales Reps Before Building 20 Consecutive Profitable Quarters
Greg Lucier touched $40B of healthcare M&A across Life Technologies, NuVasive, and Corza Medical. Here's the medtech serial acquirer strategy founders should study.
Kevin Rocco built BioRez into a $250M ConMed acquisition by engineering surgeon demand pre-launch. Here's the sports-medicine playbook founders should study.
Ray Cohen and Tom West named the three ways medtech VC incentives sabotage the best exits at MD&M 2026. Here's the breakdown founders need.
The Prometheus Biosciences Merck acquisition compounded a $700M IPO into a $10.8B exit on precision medicine sequencing. Here's how CEO Mark McKenna built it.
A medtech reimbursement strategy that compounds starts two years before FDA clearance. Here's the sequence VAC operators tell founders to follow.
Most medical device commercialization plans miss six structural gaps that kill cleared products before year two. Here's the diagnostic founders need.
Category design captures 76% of profits in any new market. Here's what Bruce Cleveland teaches medtech founders about doing the work pre-launch.
Most healthcare SEO agencies chase volume when medtech buyers run on authority. Here's what Neil Patel teaches medtech founders about agency selection.
Medical device market access decisions set the real launch date. Here's why payers, IDNs, and VACs need engineering work two years before FDA clearance.
How Intuitive Surgical's Commercial Strategy Built a $200B Pull-Driven Market Around da Vinci
Omar explains RA Capital's Elephant Slide board meeting framework and how MedTech CEOs can use it to show the whole company picture before any department update.
A medical device go-to-market strategy that compounds across stages runs on distribution efficiency, not on rep headcount. Here's the sequence.
A disciplined medical device marketing strategy runs four sequenced disciplines before sales hire. Here's the framework Bruce Cleveland taught medtech founders.
May 2026 medtech M&A and Q1 earnings follow the same pattern. Omar Khateeb breaks down what it means for pre-traction founders.
Healthcare content marketing works as a demand-engineering engine, not a lead-capture funnel. Here's the 12-18 month sequence Bruce Cleveland teaches medtech founders.
Most medtech founders hire a marketing agency before they've defined their category — and burn a year of runway proving it.
LimFlow built a procedure category around patients everyone else had given up on. Inari Medical paid $250M to own it.
Most medtech founders skip straight to hiring sales. Bruce Cleveland's market engineering framework explains why that's the wrong sequence, and what to build first.
Greg Lucier took Life Technologies from $2B to a $13.6B exit. Here's the operating philosophy he's used to build medtech companies acquirers need to buy.
FDA clearance opens the door. Four in five medtech companies walk through it and find no one waiting.
Six exits. $17 billion combined. The founders who built them share seven lessons most medtech founders learn too late.
Maurice Ferré built MAKO Surgical from the most-shorted medtech stock into a $1.65B Stryker acquisition. The founding CEO tells the full story on The State of MedTech.
Most medtech founders hire a sales team right after FDA clearance. Bruce Cleveland spent 20 years in venture watching that fail.
Ray Cohen ran 20 consecutive quarters beating analyst expectations before Boston Scientific acquired Axonics for $3.7B.
Hosting the State of Medtech podcast I noticed a common theme as I interviewed founders, VCs, and strategics.